Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.47 |
| ▸ | ITK | Q08881 | 8/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693608 | 0.95 | GRM1 (0.46) | GRM1ITKMEN1KMT2AGAA | |
| SCHEMBL5539879 | 0.93 | GRM1 (0.41) | GRM1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4693604 | 0.91 | GRM1 (0.53) | GRM1MEN1KMT2AHTR2CSLC6A4 | |
| SCHEMBL4692988 | 0.88 | GRM1 (0.41) | GRM1MEN1KMT2ACNR2GAA | |
| SCHEMBL5544763 | 0.87 | GRM1 (0.41) | GRM1MEN1KMT2ACNR2HTR2C | |
| SCHEMBL5539815 | 0.84 | GRM1 (0.38) | GRM1ITKMEN1KMT2ANPC1 | |
| SCHEMBL4692984 | 0.84 | GRM1 (0.47) | GRM1MEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL5544773 | 0.83 | GRM1 (0.46) | GRM1ITKNPC1RAB9ACNR2 | |
| Hydrochloric Acid SCHEMBL4691962 | 0.81 | GRM1 (0.46) | GRM1ITKNPC1RAB9AGAA | |
| SCHEMBL4692246 | 0.81 | GRM1 (0.39) | GRM1MEN1KMT2ACNR2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250429-B2 | Aminomethyl-substituted thiazolobenzimidazole compounds | ASTELLAS PHARMA INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1486501-A1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | GRM1, GRIN1, GRM3 | GRM1 1/4885ITK 3595/4885MEN1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.